Evidence map›Paper›PMID 42896970›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2026

[Variant Allele Frequency Stratification and EGFR Co-mutation Characteristics 
in AKT1 E17K-mutant Non-small Cell Lung Cancer].

Dan Zhao, Deyang Xie, Nana Zhang, Lili Zhang, Kun Li, Nanying Che

Abstract readEnglish Abstract
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dan Zhao *Department of Pathology, Beijing Chest Hospital, Capital Medical University/
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Deyang Xie *Department of Pathology, Beijing Chest Hospital, Capital Medical University/
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Nana ZhangDepartment of Pathology, Beijing Chest Hospital, Capital Medical University/
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Lili ZhangDepartment of Pathology, Beijing Chest Hospital, Capital Medical University/
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Kun LiDepartment of Pathology, Beijing Chest Hospital, Capital Medical University/
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Nanying CheDepartment of Pathology, Beijing Chest Hospital, Capital Medical University/
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAKT serine/threonine kinase 1 (AKT1) E17K, the most common activating mutation of AKT1, is an established druggable driver in breast cancer; however, it is exceedingly rare in non-small cell lung cancer (NSCLC), with its clinical significance remaining unclear. Variant allele frequency (VAF) may partially reflect the clonal proportion of a mutation, offering clues to the clonal characteristics of such rare mutations. This study investigated the relationship between AKT1 E17K VAF and co-mutation with classic driver genes such as epidermal growth factor receptor (EGFR) in NSCLC, aiming to explore the potential role of this mutation in tumor clonal evolution.

methodsNext-generation sequencing (NGS) data of lung cancer patients at Beijing Chest Hospital, Capital Medical University from June 2019 to April 2026 were retrospectively analyzed. After deduplication of 13,003 tests, 11,368 unique patients (including small cell lung cancer) were identified, among whom 35 harbored AKT1 E17K mutations (overall detection rate 0.31%), all being NSCLC; 5 external consultation cases were excluded, leaving 30 cases for analysis. Continuous VAF analysis was designated as the primary analysis, with an exploratory cutoff of 10%.

resultsOf the 30 patients, 20 (66.7%) were adenocarcinoma. Median follow-up was 12 months (range: 1-55 months). The EGFR co-mutation rate was lower in the high-VAF group (≥10%, n=17) than in the low-VAF group (<10%, n=13; 11.8% vs 46.2%), reaching nominal significance before correction [P=0.049, odds ratio (OR)=0.156] but not after Bonferroni adjustment (adjusted P=0.246). The median VAF was lower in the EGFR co-mutated group than in the EGFR wild-type group (1.37% vs 13.73%, P=0.071). Continuous analysis showed a negative trend between VAF and EGFR co-mutation (ρ=-0.340, P=0.066). After adjusting for histological type using Firth-corrected Logistic regression, the direction of the association remained unchanged but was no longer nominally significant (OR=0.21, 95%CI: 0.03-1.33, P=0.097).

conclusionsAKT1 E17K VAF showed a negative trend with EGFR co-mutation; however, the association did not remain significant after correction for multiple comparisons or adjustment for histological type, and may be partly influenced by histological composition. These findings should be regarded as hypothesis-generating and require validation in larger multi-center cohorts.

Indexed as

Carcinoma, Non-Small-Cell LungGene FrequencyLung NeoplasmsMutationProto-Oncogene Proteins c-aktAdultAgedAged, 80 and overErbB ReceptorsFemaleHumansMaleMiddle AgedRetrospective StudiesAKT1 protein, humanEGFR protein, humanErbB ReceptorsProto-Oncogene Proteins c-aktAKT1Clonal evolutionCo-mutationE17KEGFRLung neoplasmsVariant allele frequency

Identifiers

PMID42896970
PMCPMC13688442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.